Wall Street ended Tuesday nearly flat as bank earnings gave mixed signals and memory-chip stocks sold off for a second day. Wednesday brings September CPI at 8:30 a.m. ET and a before-the-bell lineup that includes Bank of America, Morgan Stanley, BlackRock and ASML. Underneath the headlines, a dating app agreed to a $1.3 billion buyout, an AI data-center developer jumped on an AMD deal, and another AI infrastructure stock slid toward its 52-week low. Here are the 10 stocks to watch tomorrow, a mix of smaller, lesser-known names and a few bigger reporters, with the levels that matter for Wednesday, October 14.
Stocks to Watch Tomorrow: Tuesday’s Market Snapshot
| Metric | Tuesday Close / Reading |
|---|---|
| Dow Jones Industrial Average | 51,670.10 (-0.35%) |
| S&P 500 | 7,805.45 (-0.02%) |
| Nasdaq Composite | 27,204.38 (-0.15%) |
| Russell 2000 | 2,783.56 (-0.39%) |
| 10-Year Treasury Yield | ~5.23% |
| VIX | ~15.4 |
| WTI Crude | ~$93.7 in morning trade |
| Gold / Bitcoin | ~$4,180 / ~$83,400 |
Stocks closed little changed as JPMorgan, Goldman Sachs, Citigroup and Wells Fargo all reported. JPMorgan missed on EPS ($5.57 against roughly $5.90 expected) while Goldman earned $17.01 a share, and Citigroup fell about 5.5% while Johnson & Johnson dropped nearly 6%. Memory stocks fell again after the Kospi dropped more than 6% overnight.
Wednesday’s setup: September CPI is due at 8:30 a.m. ET, with headline inflation expected at +0.6% on the month and 3.6% on the year, and the Fed’s Beige Book follows at 2 p.m. New York Fed President John Williams said one more rate hike still looks appropriate. Bank of America, Morgan Stanley, BlackRock and ASML all report before the open.
Data note: Closes are Tuesday, October 13 figures where we could verify them. Several names below show a “last verified” price with a date because a final Tuesday close was not available at press time; check live quotes before acting. Prices marked “est.” are derived from other verified figures (an offer price, a market cap or a percentage move). RSI and MACD are omitted where feeds were stale. Support and resistance levels are analytical zones built from verified prices, offer prices, 52-week extremes and round numbers, not guaranteed targets.
1. Bumble (BMBL) | ~$5.9–$6.0 est. (+57% Tuesday morning) | The $6.05 Cash Buyout Cap
A 138% Premium, a $1.3 Billion Take-Private and a Stock Priced Within Pennies of the Offer
Bumble agreed to be acquired by Ithaca Holdings for $6.05 a share in cash, valuing the company at $1.3 billion, a 138% premium to its unaffected October 9 close.
| Metric | Value |
|---|---|
| Price | ~$5.9–$6.0 est. (derived from the offer, the $2.54 unaffected close and the ~57% morning move) |
| Unaffected Close (Oct 9) | ~$2.54 (implied by the 138% premium) |
| Day’s Move | +~57% at mid-morning Tuesday after a ~50% jump Monday |
| 52-Week Range | Low ~$2.54; high not confirmed (sources differ) |
| Market Cap | ~$1.3B at the offer (about $360M before the news) |
| P/E / Dividend | Negative / None |
| Volume vs. Average | Average ~2.7M shares; surge volume not confirmed |
| Short Interest | ~10% of float (August) |
| Offer | $6.05 cash; ~119% premium to the 30-day VWAP |
| Support 1 / 2 / 3 | $5.75 / $3.80 / $2.54 |
| Resistance 1 / 2 / 3 | $6.05 (offer) / ~$6.25 / ~$6.50 |
Catalyst & Latest News: Ithaca’s co-CEOs will become Bumble’s co-CEOs, and founder Whitney Wolfe Herd approved the deal by written consent after recusing herself from the board vote. Reports of advanced talks lifted shares nearly 50% on Monday.
Technicals: The stock now trades like a merger-arbitrage name, so the offer price is a ceiling unless a rival bidder emerges. The $3.80 level is Monday’s estimated close.
Fundamentals: Bumble was down about 95% from its 2021 IPO before the news. Blackstone still held roughly 23% as of May.
Bull Case: A 1–3% spread to the offer with a signed deal and shareholder consent from the founder. Bear Case: Regulatory or financing risk, a thin spread, and a downside gap of more than 50% if the deal broke.
What to Watch:
- The spread to $6.05
- Any topping-bid chatter
- Expected closing timeline
Forecast: Expect trading in a tight $5.75–$6.05 band. A break under $5.75 would signal deal doubt.
Why This Matters: BMBL is a case study in how a buyout turns a collapsed stock into a pinned one.
2. Fermi (FRMI) | Last Verified Close $7.12 (Aug 11); +18% Tuesday Morning | AMD Backs the Matador Lease
AMD Credit Support Lifts the Pre-Revenue Data-Center Developer 18%
Fermi jumped about 18% on Tuesday after entering a credit support agreement with AMD that supports the lease for phase one of its flagship Project Matador.
| Metric | Value |
|---|---|
| Last Verified Close | $7.12 (Aug 11); final Oct. 13 close not confirmed |
| Day’s Move | +~18% at mid-morning Tuesday |
| 52-Week Range | $4.47 – $36.99 |
| Market Cap | ~$3.6B (late August) |
| P/E / Dividend | Negative / None |
| Volume vs. Average | Average ~19M shares (August data) |
| Analyst View | Mizuho Outperform, $11 target; one cited target of $17 |
| Key Stat | 15-year, ~$6.5B TensorWave lease; 222 MW first phase |
| Support 1 / 2 / 3 | $7.12 / $6.78 / $4.47 |
| Resistance 1 / 2 / 3 | $8.00 / $11.00 / $17.00 |
Catalyst & Latest News: The first binding lease, a $6.5 billion, 15-year deal with TensorWave, was announced in August, and the facility is designed for AMD Instinct GPUs. AMD’s credit support addresses the financing question that has hung over the project.
Technicals: The August lease took shares from the $5s to above $7 on heavy volume, and the AMD news extends the move.
Fundamentals: Fermi is pre-revenue and unprofitable, with Project Matador expecting deliveries in the second half of 2027. It has permitted 6 GW of a planned 17 GW and invested more than $1.5 billion.
Bull Case: Anchor tenant, AMD backing and 650 MW of expansion rights. Bear Case: Heavy cash burn, a financing-dependent build and a 52-week high of $36.99 that is far away.
What to Watch:
- Whether the Tuesday gain holds
- Financing details tied to AMD’s support
- Any second tenant
Forecast: Holding above $7.12 keeps the rebound intact. A fade through $6.78 would erase it.
Why This Matters: FRMI shows how a credit backstop can matter more than a lease headline.
3. Cipher Digital (CIFR) | Last Verified Close $13.52 (Oct 9); -11.7% Tuesday Midday | Testing the 52-Week Low
The AI-Hosting Stock Down 45% Since June Slides Into Its Yearly Low
Cipher Digital closed at $13.52 on October 9, down 44.8% from its June 30 close, then fell about 11.7% at midday Tuesday per TheStreet’s movers list.
| Metric | Value |
|---|---|
| Last Verified Close | $13.52 (Oct 9); a ~11.7% midday drop Tuesday puts it near ~$12 est. |
| 52-Week Range | $11.72 – $30.14 |
| Market Cap | ~$5B est. (about 405M shares) |
| P/E / Dividend | Negative / None |
| Volume vs. Average | Average ~25M shares |
| Analyst View | Average target ~$30 (~125% above $13.52) |
| Key Stat | Down ~45% since June 30; rent collection at Barber Lake begins in October |
| Support 1 / 2 / 3 | $11.72 / $11.00 / $10.00 |
| Resistance 1 / 2 / 3 | $13.52 / $15.77 / $16.42 |
Catalyst & Latest News: Rising Treasury yields, a weaker Bitcoin and a report on OpenAI’s revenue run-rate pressured data-center stocks earlier this month. Management said rent collection at Barber Lake starts this month.
Technicals: The stock reached $16.42 early in October and sat at $13.66 on October 8, so $13.52 (Oct. 9) and $15.77 (an August close) are reference levels.
Fundamentals: Debt is close to the company’s market value, sales have fallen for consecutive quarters, and more equity may be needed for large new projects.
Bull Case: A 52-week-low entry, Barber Lake rent starting, and a Street target near $30. Bear Case: Debt, dilution risk and a sector under pressure from yields.
What to Watch:
- A hold of $11.72
- Rent collection confirmation
- CPI-driven yield moves
Forecast: A close under $11.72 would mark a new 52-week low. Reclaiming $13.52 would be the first sign of stabilization.
Why This Matters: CIFR is the sector’s rate-sensitivity test, with CPI due before the open.
4. AZZ Inc. (AZZ) | Est. ~$140–$147 | Record Quarter, Raised Guidance, 20% Dividend Hike
The Galvanizing Giant Posts a Record Quarter and Lifts Its Outlook
AZZ reported record fiscal Q2 sales of $486.9 million, up 16.7%, and adjusted EPS of $2.00, up 29%, against a $1.79 consensus.
| Metric | Value |
|---|---|
| Price | ~$140–$147 est. (Aug 20 close $139.43; Q2 buyback average $146.71) |
| Day’s Move | Reaction not confirmed (release dated Oct 13) |
| 52-Week Range | Not confirmed |
| Market Cap | ~$4.2B est. |
| P/E / Dividend | Not confirmed / $0.24 quarterly (raised 20%) |
| Volume vs. Average | Not confirmed |
| Analyst View | Consensus “Moderate Buy” (older data) |
| Q2 Results | Sales $486.9M; Metal Coatings $233.5M (+22.9%); adjusted EPS $2.00 vs. $1.79 |
| FY27 Guidance | Raised (prior EPS range $6.75–$7.15; sales $1.80–$1.85B) |
| Support 1 / 2 / 3 | $139.43 / $135.00 / $125.00 |
| Resistance 1 / 2 / 3 | $146.71 / $150.00 / $155.00 |
Catalyst & Latest News: AZZ raised fiscal 2027 guidance, cut debt by $15 million, repurchased $20 million of stock and completed the Seattle Galvanizing acquisition. Check whether the first reaction came Tuesday or comes Wednesday.
Technicals: The Earnings-AVWAP sits near $145.80, and the stock had drifted about 5% lower since July’s report, so $146.71 is first resistance.
Fundamentals: The company generated $140 million in operating cash in the first half, and GAAP EPS of $1.94 fell 34% because of AVAIL JV earnings effects.
Bull Case: A 29% adjusted EPS jump, a beat of about 12%, a raised outlook and a dividend hike. Bear Case: GAAP EPS fell, the stock has been range-bound, and estimates were already rising.
What to Watch:
- The opening reaction versus $146.71
- Analyst target hikes
- Margin commentary in the call
Forecast: A close above $146.71 targets $150–$155. A fade under $139 would signal that the beat was priced in.
Why This Matters: AZZ is an industrial beat-and-raise that tests whether record quarters are still rewarded.
5. Domino’s Pizza (DPZ) | ~$290 est. (-4.8% Tuesday) | EPS Beat, Stock Falls
A Beat on Earnings and Revenue Isn’t Enough: Domino’s Slides Toward Its 52-Week Low
Domino’s reported EPS of $4.60 against $4.36 expected and revenue of $1.18 billion against $1.17 billion, yet shares fell about 4.8%.
| Metric | Value |
|---|---|
| Price | ~$290 est. (derived from a $9.87B market cap); final close not confirmed |
| Day’s Move | -4.76% |
| 52-Week Range | ~$282 – $464 |
| Market Cap | ~$9.9B |
| P/E (Forward) | ~17x (September estimate) |
| Dividend | ~$7.96/yr (~2.7% at the estimated price) |
| Volume vs. Average | Not confirmed |
| Short Interest | ~9% of float (older data) |
| Q3 Results | EPS $4.60 vs. $4.36; revenue $1.18B vs. $1.17B |
| Support 1 / 2 / 3 | $282 / $270 / $250 |
| Resistance 1 / 2 / 3 | $300 / $312 / $330 |
Catalyst & Latest News: Domino’s guided U.S. same-store sales growth down to low single digits after a weak April quarter. Order counts have risen while average order value has slipped, per TIKR’s review of an earlier quarter.
Technicals: The stock is about 38% below its 52-week high and sits near a low of roughly $282, and Wednesday’s follow-through matters.
Fundamentals: A forward P/E around 17x is well below its five-year average in the mid-20s, and the dividend has grown for 12 years.
Bull Case: A double beat and a cheap multiple. Bear Case: Same-store sales guidance cut, weaker order value and a stock near its low.
What to Watch:
- A hold of $282
- Same-store sales detail from the call
- Analyst target changes
Forecast: Holding $282 supports a bounce toward $300. A break lower targets $270.
Why This Matters: DPZ is a quick-service read on a stretched pizza consumer.
6. Eupraxia Pharmaceuticals (EPRX) | Price $7.32 (Oct 12) | Analysts Pile In Ahead of a December Catalyst
A $480 Million Biotech With 11 Analysts, a $16 Average Target and a Once-a-Year EoE Shot
Eupraxia’s EP-104GI showed continued remission signals at 52 weeks in high-dose cohorts, and three bullish analyst reports followed.
| Metric | Value |
|---|---|
| Price | $7.32 (Oct 12); Oct 2 close $7.24 (-7.5%) |
| 52-Week Range | ~$5.25 – $9.32 |
| Market Cap | ~$480M |
| P/E / Dividend | Negative (EPS about -$1.02) / None |
| Volume vs. Average | Oct 2: 1.71M vs. ~494K average |
| Analyst View | 11 analysts, Strong Buy; average target ~$16.35 |
| Next Catalyst | Interim Phase 2b randomized data in December 2026 |
| Support 1 / 2 / 3 | $7.19 / $6.67 / $5.25 |
| Resistance 1 / 2 / 3 | $7.83 / $8.14 / $9.32 |
Catalyst & Latest News: Oppenheimer initiated at Outperform with a $17 target, and the company plans to expand the Phase 2b portion of RESOLVE to at least 120 patients. William Blair sees peak sales above $900 million.
Technicals: The stock gapped down 7.5% on October 2 on heavy volume and has traded near $7.2–$7.3 since.
Fundamentals: A $63.2 million public offering funded further trials, and EP-104IAR is also in Phase III for knee osteoarthritis. The lead competitor is Sanofi’s Dupixent.
Bull Case: Durable one-year data, analyst targets double the price, and a December readout. Bear Case: Early open-label data from small cohorts, and cash needs.
What to Watch:
- A hold of $7.19
- Any update ahead of December
- Competitor EoE data
Forecast: A close above $7.83 targets $8.14 and then the $9.32 high. Losing $6.67 puts $5.25 in play.
Why This Matters: EPRX is a pre-catalyst biotech where positioning builds ahead of data.
7. ASML (ASML) | Last Verified ~$1,776 (Oct 10) | Earnings Before the Open With a 6% Move Priced In
The Chip-Equipment Bellwether Reports Into a Memory-Stock Rout
ASML reports Q3 results before the open Wednesday, and options price a move of roughly 5.5% to 6.2%.
| Metric | Value |
|---|---|
| Last Verified Price | ~$1,776 (about Oct 10); Tuesday’s close not confirmed |
| 52-Week Range | $715.99 – $1,991.64 |
| Market Cap | ~$670B (August data) |
| P/E (Forward) | ~32.9x (early October) |
| Dividend | ~0.5% yield |
| Volume vs. Average | Not confirmed |
| Analyst View | No Sell ratings; mean target ~$2,033 (range $1,650–$2,623) |
| Q3 Consensus | EPS ~$12.07–$12.54 |
| Options-Implied Move | ±6.2% (~$1,666 – $1,887) |
| Support 1 / 2 / 3 | $1,666 / $1,650 / $1,500 |
| Resistance 1 / 2 / 3 | $1,776 / $1,887 / $1,991 |
Catalyst & Latest News: ASML has raised guidance twice and removed a key forward number, and the report lands after a two-day memory-stock selloff on Chinese competition worries. Moomoo called it the week’s most important semiconductor print.
Technicals: The options-implied range of $1,666–$1,887 brackets the stock, with the $1,991.64 high about 12% above.
Fundamentals: The stock fell 16% after October 2024 results and 13% after July 2024’s, and the average post-earnings move is about 7%.
Bull Case: Monopoly EUV position, no Sell ratings and targets above $2,000. Bear Case: A 33x forward multiple, AI-capex crowding and a history of sharp downside reactions.
What to Watch:
- 2027 bookings and guidance
- China commentary
- Reaction versus the $1,666 lower bound
Forecast: A guidance-driven beat could reclaim $1,887. A miss would likely test $1,666 and then $1,650.
Why This Matters: ASML is the clearest read on whether the chip rout is a pause or a break.
8. BlackRock (BLK) | Last Verified $1,058.29 (Sept 30) | Asset-Flow Report With a 6% Move Priced In
The World’s Largest Asset Manager Reports Into Rising Rates
BlackRock reports before the open Wednesday, with analysts expecting EPS of about $14.25 on revenue near $7.56 billion.
| Metric | Value |
|---|---|
| Last Verified Close | $1,058.29 (Sept 30); Tuesday’s close not confirmed |
| 52-Week High | $1,219.94 (Oct 15, 2025) |
| Market Cap | ~$159B (older data) |
| P/E / Dividend | Not confirmed / ~2.1% yield |
| Volume vs. Average | Average ~800K shares (older data) |
| Analyst View | Average target ~$1,260; Morgan Stanley Overweight, $1,479 target |
| Q3 Consensus | EPS ~$14.24–$14.25 (+21%); revenue ~$7.5B (+14%) |
| Options-Implied Move | ±6.1% |
| Support 1 / 2 / 3 | $1,000 / $950 / $900 |
| Resistance 1 / 2 / 3 | $1,060 / $1,122 / $1,174 |
Catalyst & Latest News: BlackRock beat estimates last quarter ($13.91 adjusted vs. $12.67), and one market commentator argues the group is priced for disappointment with rates rising. Integrating HPS and GIP is a stated risk.
Technicals: The stock’s average earnings-day move is about 3.3% to 3.8%, well under the ±6.1% options now imply.
Fundamentals: The stock rose 7% ahead of the July report to $1,097.84, and Earnings Whispers shows prices between about $1,122 and $1,174 on other dates, so confirm the live quote.
Bull Case: A 21% EPS growth estimate, flow momentum and private-markets expansion. Bear Case: Rate pressure, strategists turning cautious on U.S. stocks, and integration risk.
What to Watch:
- Net flows and fee rate
- Private-markets commentary
- Reaction versus the ±6% options range
Forecast: A flow-driven beat could reclaim $1,122. A miss would likely retest $1,000.
Why This Matters: BLK shows where investor money is flowing as yields climb.
9. Pershing Square (PS) | Last Verified ~$54.6 (Sept 29); -12% Tuesday Midday | Ackman’s Stock Trades Far Above Its Targets
The Ackman Vehicle Sheds 12% After a Run to $59.94
Pershing Square fell about 12% at midday Tuesday, leading TheStreet’s list of decliners.
| Metric | Value |
|---|---|
| Last Verified Price | ~$54.6 (Sept 29, after a 7.6% drop from $59.17); Tuesday’s close not confirmed |
| Day’s Move | -~12% at midday Tuesday |
| 52-Week High | $59.94 (Sept 28) |
| Market Cap | ~$23.7B at the late-September peak |
| P/E / Dividend | Not meaningful / ~0.2% yield |
| Volume vs. Average | Not confirmed |
| Analyst View | Hold; average target ~$41.33; one downgrade to Hold with target withdrawn |
| Key Stat | Q2 distributable EPS $0.14 vs. $0.12 expected |
| Support 1 / 2 / 3 | $50.00 / $41.33 / $34.00 |
| Resistance 1 / 2 / 3 | $54.60 / $59.17 / $59.94 |
Catalyst & Latest News: An analyst downgraded the stock to Hold after its run, saying it had passed the old $42 target. The stock jumped 13.7% in one session on September 18.
Technicals: The stock traded as low as the mid-$30s in May and sits far above the $41.33 average target.
Fundamentals: PS is the fee-earning parent of Ackman’s hedge-fund business and Pershing Square USA, with a closed-end vehicle at its core.
Bull Case: Fee growth and the Ackman brand. Bear Case: A stock that traded well above its average target ($41.33 was about 30% below the late-September price) and a Weiss D+ rating.
What to Watch:
- A hold of $50
- Fund-flow and net-asset-value news
- Analyst target resets
Forecast: A close under $50 would point toward the $41.33 average target. A rebound above $54.60 would erase part of Tuesday’s drop.
Why This Matters: PS shows what happens when a hype-driven listing outruns its fundamentals.
10. Modular Medical (MODD) | Price $2.68 (Oct 12) | Pivot Launch Month for a $22 Million Pump Maker
A Second Look: The Insulin-Pump Launch Is Under Way and the Stock Is Still Tiny
Modular Medical began the first phase of its Pivot launch in five U.S. markets in October, and the stock appeared in Tuesday’s market commentary.
| Metric | Value |
|---|---|
| Price | $2.68 (Oct 12); Sept 10 close $2.64 |
| 52-Week Range | $1.72 – $30.00 (split-adjusted) |
| Market Cap | ~$22M |
| P/E / Dividend | Negative (EPS about -$9.85) / None |
| Volume vs. Average | Average ~289K shares |
| Analyst View | Three Buy ratings; no published targets |
| Key Stat | 1-for-30 reverse split; $3.4M registered direct offering |
| Support 1 / 2 / 3 | $2.52 / $2.48 / $1.72 |
| Resistance 1 / 2 / 3 | $2.81 / $3.61 / $4.77 |
Catalyst & Latest News: The company signed a national pharmacy benefit manager contract and received FDA clearance for software upgrades to Pivot. TNN’s penny-stock coverage explains why launches at this scale carry funding risk.
Technicals: The stock fell 6% on September 10 to $2.64 and has held a narrow band since.
Fundamentals: The stock traded near $5 in July before sliding, and dilution is part of the story.
Bull Case: A commercial launch, PBM access and a tiny market value. Bear Case: Heavy losses, repeated equity raises and a reverse split.
What to Watch:
- First-market launch metrics
- Any new financing
- A hold of $2.52
Forecast: Early uptake data could lift MODD through $2.81 toward $3.60. A financing announcement would put $2.48 at risk.
Why This Matters: MODD is a tiny device launch where one early number defines the story.
Stocks to Watch Tomorrow: Sector Sentiment Snapshot and Forecast
Financials are the main event: after a mixed Tuesday for the big banks, Bank of America, Morgan Stanley and BlackRock report before the open, and CPI at 8:30 a.m. sets the rate backdrop. Semiconductors are the pressure point, with ASML reporting into a memory-stock rout. AI infrastructure is split: Fermi gained on an AMD backstop while Cipher Digital slid toward its low as yields stay high. Restaurants and consumer names face scrutiny after Domino’s fell on a beat. Our forecast for Wednesday is two-sided and CPI-driven: a hot print would pressure rate-sensitive names like CIFR, while a cool one could spark relief in small caps.
At a Glance: Stocks to Watch Tomorrow (Oct 14, 2026)
| # | Ticker | Last Close / Price | Move | Catalyst | Key Level |
|---|---|---|---|---|---|
| 1 | BMBL | ~$5.9–$6.0 est. | +~57% | $6.05 cash buyout | $5.75 / $6.05 |
| 2 | FRMI | $7.12 (Aug 11) | +~18% | AMD credit support | $7.12 / $8.00 |
| 3 | CIFR | $13.52 (Oct 9) | -~11.7% | Near 52-week low | $11.72 / $13.52 |
| 4 | AZZ | ~$140–$147 est. | n/a | Record quarter, raised guide | $139.43 / $146.71 |
| 5 | DPZ | ~$290 est. | -4.76% | Q3 beat, stock falls | $282 / $300 |
| 6 | EPRX | $7.32 (Oct 12) | n/a | Analyst reports; Dec data | $7.19 / $7.83 |
| 7 | ASML | ~$1,776 (Oct 10) | n/a | Earnings before the open | $1,666 / $1,887 |
| 8 | BLK | $1,058 (Sept 30) | n/a | Earnings before the open | $1,000 / $1,122 |
| 9 | PS | ~$54.6 (Sept 29) | -~12% | Sell-off after run to $59.94 | $50 / $54.60 |
| 10 | MODD | $2.68 (Oct 12) | n/a | Pivot launch month | $2.52 / $2.81 |
Follow TNN for daily stock market news and financial news today.
Disclaimer: This publication is entirely for informational and journalistic purposes and does not constitute formal financial, investment, or legal advice. All market investments carry inherent risks of capital loss, and small-cap, micro-cap, clinical-stage biotech, AI-infrastructure and other high-volatility stocks carry elevated risk. Stock prices, percentage moves, and market data cited reflect figures available at the time of publication and are subject to change. Several prices are labeled “last verified” with a date or “est.” and may not reflect current trading. Support and resistance levels are analytical reference zones, not guaranteed price targets. Analyst price targets and ratings are third-party estimates and do not guarantee actual results. Always complete independent due diligence prior to executing equity trades.
About The Author
